Showing 1–3 of 3 results for author: Hilsman, J

Emerging Opportunities of Using Large Language Models for Translation Between Drug Molecules and Indications

Authors: David Oniani, Jordan Hilsman, Chengxi Zang, Junmei Wang, Lianjin Cai, Jan Zawala, Yanshan Wang

Abstract: A drug molecule is a substance that changes the organism's mental or physical state. Every approved drug has an indication, which refers to the therapeutic use of that drug for treating a particular medical condition. While the Large Language Model (LLM), a generative Artificial Intelligence (AI) technique, has recently demonstrated effectiveness in translating between molecules and their textual… ▽ More A drug molecule is a substance that changes the organism's mental or physical state. Every approved drug has an indication, which refers to the therapeutic use of that drug for treating a particular medical condition. While the Large Language Model (LLM), a generative Artificial Intelligence (AI) technique, has recently demonstrated effectiveness in translating between molecules and their textual descriptions, there remains a gap in research regarding their application in facilitating the translation between drug molecules and indications, or vice versa, which could greatly benefit the drug discovery process. The capability of generating a drug from a given indication would allow for the discovery of drugs targeting specific diseases or targets and ultimately provide patients with better treatments. In this paper, we first propose a new task, which is the translation between drug molecules and corresponding indications, and then test existing LLMs on this new task. Specifically, we consider nine variations of the T5 LLM and evaluate them on two public datasets obtained from ChEMBL and DrugBank. Our experiments show the early results of using LLMs for this task and provide a perspective on the state-of-the-art. We also emphasize the current limitations and discuss future work that has the potential to improve the performance on this task. The creation of molecules from indications, or vice versa, will allow for more efficient targeting of diseases and significantly reduce the cost of drug discovery, with the potential to revolutionize the field of drug discovery in the era of generative AI. △ Less

Submitted 16 February, 2024; v1 submitted 14 February, 2024; originally announced February 2024.

Large Language Models Vote: Prompting for Rare Disease Identification

Authors: David Oniani, Jordan Hilsman, Hang Dong, Fengyi Gao, Shiven Verma, Yanshan Wang

Abstract: The emergence of generative Large Language Models (LLMs) emphasizes the need for accurate and efficient prompting approaches. LLMs are often applied in Few-Shot Learning (FSL) contexts, where tasks are executed with minimal training data. FSL has become popular in many Artificial Intelligence (AI) subdomains, including AI for health. Rare diseases affect a small fraction of the population. Rare di… ▽ More The emergence of generative Large Language Models (LLMs) emphasizes the need for accurate and efficient prompting approaches. LLMs are often applied in Few-Shot Learning (FSL) contexts, where tasks are executed with minimal training data. FSL has become popular in many Artificial Intelligence (AI) subdomains, including AI for health. Rare diseases affect a small fraction of the population. Rare disease identification from clinical notes inherently requires FSL techniques due to limited data availability. Manual data collection and annotation is both expensive and time-consuming. In this paper, we propose Models-Vote Prompting (MVP), a flexible prompting approach for improving the performance of LLM queries in FSL settings. MVP works by prompting numerous LLMs to perform the same tasks and then conducting a majority vote on the resulting outputs. This method achieves improved results to any one model in the ensemble on one-shot rare disease identification and classification tasks. We also release a novel rare disease dataset for FSL, available to those who signed the MIMIC-IV Data Use Agreement (DUA). Furthermore, in using MVP, each model is prompted multiple times, substantially increasing the time needed for manual annotation, and to address this, we assess the feasibility of using JSON for automating generative LLM evaluation. △ Less

Submitted 23 January, 2024; v1 submitted 24 August, 2023; originally announced August 2023.

From Military to Healthcare: Adopting and Expanding Ethical Principles for Generative Artificial Intelligence

Authors: David Oniani, Jordan Hilsman, Yifan Peng, COL, Ronald K. Poropatich, COL Jeremy C. Pamplin, LTC Gary L. Legault, Yanshan Wang

Abstract: In 2020, the U.S. Department of Defense officially disclosed a set of ethical principles to guide the use of Artificial Intelligence (AI) technologies on future battlefields. Despite stark differences, there are core similarities between the military and medical service. Warriors on battlefields often face life-altering circumstances that require quick decision-making. Medical providers experience… ▽ More In 2020, the U.S. Department of Defense officially disclosed a set of ethical principles to guide the use of Artificial Intelligence (AI) technologies on future battlefields. Despite stark differences, there are core similarities between the military and medical service. Warriors on battlefields often face life-altering circumstances that require quick decision-making. Medical providers experience similar challenges in a rapidly changing healthcare environment, such as in the emergency department or during surgery treating a life-threatening condition. Generative AI, an emerging technology designed to efficiently generate valuable information, holds great promise. As computing power becomes more accessible and the abundance of health data, such as electronic health records, electrocardiograms, and medical images, increases, it is inevitable that healthcare will be revolutionized by this technology. Recently, generative AI has captivated the research community, leading to debates about its application in healthcare, mainly due to concerns about transparency and related issues. Meanwhile, concerns about the potential exacerbation of health disparities due to modeling biases have raised notable ethical concerns regarding the use of this technology in healthcare. However, the ethical principles for generative AI in healthcare have been understudied, and decision-makers often fail to consider the significance of generative AI. In this paper, we propose GREAT PLEA ethical principles, encompassing governance, reliability, equity, accountability, traceability, privacy, lawfulness, empathy, and autonomy, for generative AI in healthcare. We aim to proactively address the ethical dilemmas and challenges posed by the integration of generative AI in healthcare. △ Less

Submitted 4 August, 2023; originally announced August 2023.